Status:
COMPLETED
Gonadotropin-Releasing Hormone (GnRH)-Antagonist Therapy in Rheumatoid Arthritis
Lead Sponsor:
Betanien Hospital
Collaborating Sponsors:
Norwegian Foundation for Health and Rehabilitation
University of Oslo
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to compare the safety and efficacy of gonadotropin-releasing hormone (GnRH) antagonist therapy versus placebo in patients with moderate to severe rheumatoid arthritis.
Eligibility Criteria
Inclusion
- Adult between 18 years and above
- Moderate to severe disease activity
- Negative pregnancy test for women of childbearing potential
- Use of reliable method of contraception (non-hormonal) by sexually active female patients
Exclusion
- Patients who are pregnant or breastfeeding
- Patients taking biologic therapy or prednisolone \>7.5mg
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2011
Estimated Enrollment :
104 Patients enrolled
Trial Details
Trial ID
NCT00667758
Start Date
May 1 2008
End Date
October 1 2011
Last Update
August 6 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Deaprtment of Rheumatology, Betanien Hospital
Skien, Norway